HARmonized Protocol Template to Enhance Reproducibility (HARPER)

Clinical trials have detailed study protocols and are registered on ClinicalTrials.gov. What level of details are needed for real-world data (RWD) analyses that aim to estimate treatment effects? In Europe, the European Medicines Agency (EMA) requires registration of many study protocols using a template for observational post-authorization safety studies (PASS) conducted by marketing authorization holders.…

Meet me at ISPOR 2022

I’ll be attending ISPOR 2022 in Washington DC next week. It’ll be great to see a number of my peers in person after two years of virtual meetings. One of my research papers that will be presented is titled “Economic Impact of Sequential Testing for COVID-19 and Influenza with Molecular Point of Care in 3…

My ISPOR Europe 2021 Panels

If you are attending the ISPOR Europe 2021 conference, please check out my panels on the following topics: “Addressing Payment Challenges for Alzheimer’s Disease-Modifying Therapies” on December 1, 16:00-17:00 CET with Jakub Hlavka, Howard Thom, and Adrian Towse. “Challenges in Quantifying the Value of Digital Therapeutics” on December 2, 11:00-12:00 CET with Wayne Burton, Megan…

ISPOR Europe Panels

Mark your calendars and be sure to register: I will be speaking on two panels at the upcoming ISPOR Europe 2021 virtual conference. These panels include: “Addressing Payment Challenges for Alzheimer’s Disease-Modifying Therapies” on December 1, 16:00-17:00 CET and “Challenges in Quantifying the Value of Digital Therapeutics” on December 2, 11:00-12:00 CET. Further event details…

ISPOR Summit on Value Assessment

On June 10, I will be presenting at ISPOR’s Summit on “Value Assessment: New Insights, Approaches, and Applications,” which will highlight evolving practices, new methods, and practical applications in value assessment. The Summit will provide a multistakeholder perspective, including recent developments in the incorporation of uncertainty and risk aversion into value measures, covering both the…

At ISPOR: The effect of RA medication choice on costs

For those who are attending the International Society For Pharmacoeconomics and Outcomes Research (ISPOR) conference this next week in Baltimore, please check out my poster titled: THE EFFECT OF MEDICATION CHOICE AFTER TUMOR NECROSIS FACTOR INHIBITOR (TNFI) USE ON THE HEALTHCARE COSTS FOR PATIENTS WITH RHEUMATOID ARTHRITIS: AN INSTRUMENTAL VARIABLES APPROACH My co-authors are Ahva…